A phase 2 study of efficacy and safety of NS-089/NCNP-02 in Duchenne muscular dystrophy patients
Latest Information Update: 09 Aug 2023
At a glance
- Drugs Brogidirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Nippon Shinyaku
Most Recent Events
- 07 Aug 2023 According to NS Pharma media release, additional details will be provided once the trial is ready to begin enrolling participants.
- 11 Jul 2023 New trial record
- 07 Jul 2023 According to NS Pharma media release, clinical development of NS-089/NCNP-02 includes this planned Phase 2 study conducted in Japan by Nippon Shinyaku, Additional details will be provided once the trials are ready to begin enrolling participants